SCHEMBL5335337

SCHEMBL5335337

COC(=O)Cn1ccc(-c2cc(Oc3cccc(N)c3)ncn2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
LMNA P02545 1/20 0.41
NPC1 O15118 3/20 0.39
RAB9A P51151 3/20 0.39
ALDH1A1 P00352 1/20 0.39
MAP2K7 O14733 5/20 0.38
CYP1A2 P05177 2/20 0.36
CYP2C19 P33261 2/20 0.36
RECQL P46063 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
CYP2C9 P11712 1/20 0.35
TSHR P16473 1/20 0.35
EGFR P00533 2/20 0.35
ABL1 P00519 1/20 0.35
SRC P12931 1/20 0.35
ABL2 P42684 1/20 0.35
AKR1B1 P15121 1/20 0.34
LOXL2 Q9Y4K0 1/20 0.34
ROCK1 Q13464 1/20 0.34
ERBB2 P04626 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5316650 0.89 MAP2K7 (0.40) MAPTLMNANPC1RAB9AALDH1A1
SCHEMBL5318717 0.89 NPC1 (0.39) MAPTLMNANPC1RAB9AALDH1A1
SCHEMBL5452651 0.82 MAPT (0.42) MAPTLMNANPC1RAB9AALDH1A1
SCHEMBL5449072 0.82 SMN1; SMN2 (0.39) MAPTLMNANPC1RAB9AALDH1A1
SCHEMBL5450857 0.82 MAP2K7 (0.43) MAP2K7
SCHEMBL5333941 0.79 SMN1; SMN2 (0.43) MAPTLMNANPC1RAB9AALDH1A1
SCHEMBL5453207 0.77 KDR (0.58)
SCHEMBL5425080 0.74 MAP2K7 (0.43) MAP2K7
SCHEMBL5339896 0.73 KDR (0.45) MAPTLMNANPC1RAB9AMAP2K7
SCHEMBL5426814 0.72 MAP2K7 (0.45) MAP2K7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 MAPT 2911/4885LMNA 4180/4885NPC1 4325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.